COMMON MAPS
Map version new-york activity top-down
Main site Contact
Menu
↑ parent activity group ·
research dossier

CANINE CANCER FOUNDATION INC
EAST HAMPTON, NY · EIN 883261140 · Form 990EZ · FY2025 · NTEE D20 · Animal-Related · Micro (<$100K) · hemangio.com
revenue
$2K
expenses
$7K
net assets
$84K
employees
—
mission · from form 990

Canine Cancer Foundation is currently in its infancy stage and establishing itself to raise public awareness of canine cancer, including canine hemangiosarcoma, and to disseminate and provide educational resources and support for families of canine cancer patients, veterinary professionals, and the general public.

profile · synthesized from sources

The website content focuses on a compilation of clinical trials and diagnostic information related to canine hemangiosarcoma, hosted or curated by various veterinary institutions and research centers. It provides detailed descriptions of ongoing studies, treatment approaches, and diagnostic protocols but does not describe the activities, mission, or structure of a specific nonprofit organization. The content appears to be informational and research-oriented, likely serving veterinarians, researchers, and dog owners seeking advanced medical insights.

named programs · 4 · from sources

What they call their work

Ethos Precision Medicine Umbrella Study for Hemangiosarcoma (ETHOS-PUSH)
Genomically guided clinical trial matching novel drugs to specific molecular subtypes of hemangiosarcoma in dogs, aiming to improve outcomes and potentially cure the disease.
Investigating Volatile Organic Compounds as Potential Markers of Canine Hemangiosarcoma
Research using trained bio-detection dogs to identify unique odor profiles associated with hemangiosarcoma, exploring non-invasive early diagnostic methods.
Scout Out Canine Hemangiosarcoma (SOCH) Study
Randomized, blinded, placebo-controlled trial evaluating a multivalent peptide vaccine to stimulate immune detection and destruction of hemangiosarcoma cells in dogs.
Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up (Shine On Project)
Long-term study testing the efficacy of the drug eBAT in preventing or delaying the onset of hemangiosarcoma in dogs by altering tumor microenvironment and immune response.
activities · 4 groups

What they do

  • Cancer Peer Support & Wellness Programs 1 activity
    • Building community and peer support networks
      Facilitates online community spaces and peer support platforms where pet owners affected by hemangiosarcoma can connect, share experiences, and receive emotional support.
  • Healthcare Provider Directories and Clinical Support Services 1 activity
    • Facilitating access to veterinary care and clinical trials
      Supports families in locating veterinary specialists through directories and remote consultation tools, provides information on ongoing clinical trials, and assists with enrollment of dogs into hemangiosarcoma research studies.
  • Cancer Patient Financial and Practical Support 1 activity
    • Providing financial assistance and support for cancer care costs
      Offers financial aid to families facing cost barriers in treating canine hemangiosarcoma and provides information on available financial support options.
  • Uncategorized 5 activities
    • Administering ozonated glycerin treatment for canine hemangiosarcoma
      Provides intraperitoneal ozonated glycerin injections to canine patients with splenic and liver hemangiosarcoma, reporting tumor reduction, spleen regeneration, improved quality of life, and extended remission periods. Over 300 injections have been administered across at least 50 dogs.
    • Conducting preclinical and clinical research on hemangiosarcoma therapies
      Conducts pilot studies and preclinical research on experimental treatments for canine hemangiosarcoma, including OXC-101, boron neutron capture therapy (BNCT), eBAT combination therapy, and liquid biopsy for early detection. Research includes in vitro studies, animal trials, and retrospective analysis to assess treatment efficacy, safety, and biomarkers.
    • Developing professional resources for veterinary practitioners
      Provides a dedicated resource section for veterinary professionals with up-to-date information on hemangiosarcoma diagnosis, treatment protocols, and patient care strategies.
    • Offering guidance on complementary and integrative cancer care
      Recommends and provides information on complementary approaches such as ketogenic diets, fasting, mushroom extracts (e.g., Turkey Tail), Chinese herbs (e.g., Yunnan Baiyao), and K9 Immunity Plus to support tumor management and reduce internal bleeding in dogs with hemangiosarcoma.
    • Providing educational and emotional support resources for pet owners
      Offers comprehensive educational materials and psychosocial support for caregivers of dogs with hemangiosarcoma, including webinars, downloadable guides, FAQs, quality-of-life charts, diagnosis checklists, and blog content addressing emotional challenges, euthanasia timing, and managing caregiver burden.
financials · form 990EZ · fy2025
revenue
Total revenue$2K
Contributions & grants$2K100%
Program service revenue——
Investment income——
Other revenue—
expenses
Total expenses$7K
Program expenses—
Admin / overhead—
Fundraising—
Salaries & benefits—
Grants paid out$7K
balance sheet
Total assets$84K
Cash—
Investments—
Liabilities—
Net assets$84K
3 years on record · 2023–2025 · YoY revenue -7.7%
leadership · form 990 part vii · fy2025

Who runs it

board members · 3
  • Amanda Redlus — Secretary, Director
  • Jason Redlus — President, Treasurer, Director
  • Josh Wolfe — Director
relationships · 20

Who they work with

  • AKC Canine Health Foundation Partner — Collaborates on multiple clinical trials related to canine hemangiosarcoma, including studies on propranolol and doxorubicin, genomic insights, glutamate signaling, GD3 liposomal vaccine, and volatile organic compound detection.
  • American Association for Cancer Research Network — Presented research findings at the AACR Annual Meeting.
  • American Association for Cancer Research Partner — Presented pilot study findings on OXC-101 at AACR Annual Meeting.
  • American Association for Cancer Research Partner — Presented research findings on OXC-101 in dogs with hemangiosarcoma at AACR Annual Meeting.
  • Calviri Partner — Develops blood test for early detection of hemangiosarcoma.
  • Canine Cancer Alliance Partner — Collaborates with Canine Cancer Alliance to provide educational webinars and research updates on canine cancer treatments.
  • Dr. Breitschwerdt Partner — Investigates infectious links, including Bartonella, in the development of hemangiosarcoma.
  • Dr. Jim Bridges Partner — Veterinarian providing ozonated glycerin treatments and clinical insights for canine hemangiosarcoma cases.
  • Ethos Discovery Partner — Collaborates on research and development of new treatment approaches for hemangiosarcoma.
  • Facebook Partner — Hosts a community page for individuals affected by hemangiosarcoma to connect and share support.
  • Lap of Love Partner — Collaborates with Lap of Love to provide quality-of-life assessment tools for dogs with cancer.
  • Morris Animal Foundation Funder — Funds research on hemangiosarcoma, including studies on genetic markers and disease mechanisms.
  • Norwegian University of Life Sciences Partner — Researches macrophage-based immune modulation to inhibit spread of hemangiosarcoma.
  • Reddit Partner — Hosts a community forum for individuals affected by hemangiosarcoma to connect and share support.
  • UMN Partner — Collaborates on research involving eBAT therapy and blood testing for hemangiosarcoma.
  • University of Minnesota's College of Veterinary Medicine Partner — Conducts research on epigenetic drivers of tumor growth in canine hemangiosarcoma.
  • Vet Specialists Partner — Partner organization providing a tool to help locate veterinary specialists and book consultations.
  • VetVine Partner — Co-hosts educational webinars on hemangiosarcoma research and treatment.
  • WSAVA Partner — Partners with WSAVA to disseminate clinical and pet owner resources on hemangiosarcoma.
  • ogpro.org Partner — Organization through which Dr. Jim Bridges trains veterinarians in ozonated glycerin therapy.
strategies · 3

How they approach the work

Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.

  • Information Empowerment for Caregivers and Clinicians
    methodology: information_empowerment
    By providing centralized, accessible information and educational resources, the organization empowers both pet owners and veterinary professionals to make informed decisions, improving care outcomes because informed decision-making reduces uncertainty and enhances treatment adherence and clinical precision.
  • Public Education and Awareness as Prevention and Engagement Leverage
    methodology: public_education_and_awareness
    By raising public awareness and disseminating educational resources, the organization increases early detection and engagement with care because informed pet owners are more likely to seek timely intervention and adhere to recommended screening and treatment protocols.
  • Targeted, Palliative Multi-Modal Therapy for Hemangiosarcoma
    methodology: palliative_combination_therapy
    By combining individualized, low-burden therapies—including metronomic chemotherapy, metabolic support, and targeted radiation—the organization improves quality of life and slows tumor progression because this integrated, palliative approach prioritizes tolerability and biological specificity over aggressive intervention.